{ "SYNERGY-Outcomes Study for Metabolic Dysfunction-Associated Steatotic Liver Disease", "This study, called SYNERGY-Outcomes, is looking into whether two medications, tirzepatide and retatrutide, can prevent serious liver problems (Major Adverse Liver Outcomes or MALO) in adults with a high risk of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). MASLD is a condition where too much fat builds up in the liver. You might be able to join if you are an adult with MASLD and specific non-invasive test results showing certain levels of liver fat and stiffness. Participants will be randomly assigned to receive either tirzepatide, retatrutide, or a placebo (an inactive substance) through injections under the skin. The study aims to enroll about 4,500 adults and will last for approximately 224 weeks, with the main goal being to see if these medications can prevent MALO.", "design": "This is an interventional study that plans to enroll about 4,500 adult participants. Participants will be randomly assigned to receive one of two active drugs or a placebo.", "commitments": "You may have up to approximately 25 to 30 clinic visits over about 224 weeks to monitor your health, complete study procedures, and assess liver function.", "compensation": "Not stated in the trial record.", "follow_up": "Participants will be followed from Baseline up to study completion, which is about 224 weeks, to track the first occurrence of any major adverse liver outcome.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.